Stargardt's Disease: Molecular Pathogenesis and Current Therapeutic Landscape

Area of Science:

• Ophthalmology
• Genetics
• Molecular Biology

Background:

• Stargardt disease (STGD1) is an inherited macular degeneration linked to the ABCA4 gene.
• Mutations cause toxic byproduct buildup in the retinal pigment epithelium, leading to vision loss.
• Over 1200 ABCA4 variants contribute to STGD1's genetic complexity and varied presentation.

Purpose of the Study:

• To review the current landscape of Stargardt disease pathology and therapeutic strategies.
• To highlight the genetic heterogeneity and phenotypic variability of STGD1.
• To discuss the challenges and future directions in developing effective STGD1 treatments.

Main Methods:

• Literature review of STGD1 genetics, pathology, and ongoing clinical trials.
• Analysis of investigational therapies including small molecules, gene therapy, and RORA gene therapy.
• Examination of clinical trial outcomes and challenges in genotype-phenotype correlation.

Main Results:

• STGD1 is characterized by ABCA4 gene mutations, leading to lipofuscin accumulation and vision impairment.
• Numerous therapeutic approaches are under investigation, targeting different disease mechanisms.
• Clinical trials show promise but face challenges in optimizing efficacy and understanding genetic influences.

Conclusions:

• Effective STGD1 therapy requires addressing genetic heterogeneity and genotype-phenotype correlations.
• Future treatments may integrate strategies targeting oxidative stress, inflammation, and genetic repair.
• Optimizing efficacy of current and emerging therapies remains a critical goal for Stargardt disease management.